Latanoprost Al (Latanoprost)

The drug activates prostaglandin F‑type receptors in the eye, which remodels the extracellular matrix of the ciliary body and increases uveoscleral outflow of aqueous humor, resulting in reduced intra‑ocular pressure.

The dosing regimen is determined by the prescribing clinician. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact schedule should follow the prescriber’s instructions.

Safety data for Latanoprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong IOP‑lowering efficacy. Compared with beta‑blockers or carbonic anhydrase inhibitors, it often provides greater pressure reduction with a different side‑effect profile, such as increased eyelash growth.

Store the product at room temperature, below 25 °C, in the original container. Protect it from direct light and moisture. Do not freeze the solution, and keep the bottle tightly closed when not in use.

Latanoprost is applied as a single ophthalmic drop to the affected eye(s) once daily, usually in the evening. The patient should wash hands, avoid touching the tip of the bottle to the eye or any surface, and gently close the eye after instillation.

Serious risks, though rare, include severe allergic reactions, uveitis, macular edema, and paradoxical increase in intra‑ocular pressure. Patients should seek immediate medical attention if they experience sudden eye pain, vision loss, or signs of an allergic response.

Latanoprost should be avoided in patients with active ocular infections, hypersensitivity to prostaglandin analogs, or a history of severe uveitis. It is also contraindicated in individuals for whom a prostaglandin‑mediated increase in uveoscleral outflow is undesirable, as determined by the clinician.